Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aran Research & Development (1982) (XTAE:ARAN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aran Research & Development (1982) EBITDA Margin % Related Terms
Aran Research & Development (1982) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aran Research & Development (1982) EBITDA Margin % Chart
For the Conglomerates subindustry, Aran Research & Development (1982)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aran Research & Development (1982) EBITDA Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Aran Research & Development (1982)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aran Research & Development (1982)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aran Research & Development (1982) (XTAE:ARAN) has a EBITDA Margin % of 20.92% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aran Research & Development (1982) and its competitors. This is 116% above median its historical median of 9.69. Over the past decade, Aran Research & Development (1982)'s EBITDA Margin % has ranged from 7.16 to 26.58. According to the industry distribution chart, Aran Research & Development (1982) ranks #206 out of 542 companies in the Conglomerates industry, placing it in the top 38%.
Is Aran Research & Development (1982)'s EBITDA Margin % too high?
Aran Research & Development (1982)'s current EBITDA Margin % of 20.92% is 116% above median its 10-year median of 9.69. Over the past 10 years, this metric has ranged from a low of 7.16 to a high of 26.58. The Conglomerates industry median EBITDA Margin % is 12.07. Aran Research & Development (1982)'s value of 20.92% is 73.3% above this industry median. Based on the distribution chart, Aran Research & Development (1982) ranks #206 out of 542 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Aran Research & Development (1982) has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aran Research & Development (1982)'s EBITDA Margin % compare to MMM and HON?
According to the Conglomerates industry distribution chart, Aran Research & Development (1982) ranks #206 out of 542 companies for EBITDA Margin %. This puts Aran Research & Development (1982) in the upper half of its industry. The industry median EBITDA Margin % is 12.07. Aran Research & Development (1982)'s value of 20.92% is 73.3% above this benchmark. Historically, Aran Research & Development (1982)'s own EBITDA Margin % has ranged from 7.16 to 26.58 over the past decade. While the company's 10-year median is 9.69 vs. the industry median of 12.07, Aran Research & Development (1982) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Conglomerates company?
The median EBITDA Margin % among Conglomerates companies is 12.07, based on 542 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aran Research & Development (1982)'s current EBITDA Margin % of 20.92% is 73.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aran Research & Development (1982) and its competitors. For the Conglomerates industry, the median EBITDA Margin % is 12.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aran Research & Development (1982)'s current EBITDA Margin % is 20.92%, which is 116% above median its own 10-year median of 9.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aran Research & Development (1982) stock overvalued right now?
Based on GuruFocus' analysis, Aran Research & Development (1982) (XTAE:ARAN) is currently considered Fairly Valued. The stock's GF Value™ is ₪37.11, compared to a current price of ₪39.78 — trading 7.2% above its estimated fair value. The current EBITDA Margin % is 20.92%, which is 116% above median its 10-year median of 9.69 and 73.3% above the Conglomerates industry median of 12.07. Aran Research & Development (1982)'s overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aran Research & Development (1982) (XTAE:ARAN), the current EBITDA Margin % is 20.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aran Research & Development (1982) (XTAE:ARAN) Overvalued in 2026?
Based on GuruFocus' analysis, Aran Research & Development (1982) stock appears to be overvalued.
The current stock price of ₪39.78 is trading 7.2% above its estimated GF Value™ of ₪37.11.
GuruFocus considers Aran Research & Development (1982) to be Fairly Valued.
Key valuation signals for XTAE:ARAN:
EBITDA Margin %: 20.92% (116% above median its 10-year median of 9.69)
GF Value™: ₪37.11 vs. price of ₪39.78 (7.2% above fair value)
Industry Position: 73.3% above the Conglomerates median (#206 of 542)
No single metric tells the full story. See the XTAE:ARAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aran Research & Development (1982) Ltd is a product design and development company. It also manufactures equipment for the plastics industry. It develops & supplies products including medical devices, water, defense & HLS, consumer & industrial and injection molds. It also has medical startups which focuses on Cardiovascular, Laparoscopy and Gastrointestinal endoscopy.
78GF Score
Get the complete analysis for XTAE:ARAN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ARAN has been successfully added to your 
